INmune Bio up as FDA allows prostate cancer therapy study

Inmune Bio

08/05/2023 16:37

** Shares of drug developer INmune Bio Inc  INMB.O  up 8.7%
at $8.80
    ** U.S. health regulator cleared company's application to
initiate early- to mid-stage study of experimental cell therapy
to treat patients with a type of prostate cancer
    ** The study is expected to enroll the first of 30 patients
in the second half of 2023 - company
    ** Including session's gains, stock up ~38% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))